Pan-TRK positive uterine sarcoma in immunohistochemistry without neurotrophic tyrosine receptor kinase gene fusions: A case report

Table 1 Oncologic outcomes of TRK inhibitors in NTRK gene fusion positive tumors

Ref.	TRKi	Sample size	Tumor type	Objective response rate (%)	Duration of response (months)	Progression free survival (months)	Overall survival (months)
Demetri et al[9]	Entrectinib	121	Sarcoma, salivary, NSCLC, etc.	61.2	20 (95%CI: 13.0-38.2)	13.8 (95%CI: 23.4-46.4)	33.8 (95%CI: 23.4-46.4)
	Entrectinib	26	Sarcoma	57.7	15.0 (95%CI: 4.6-NE)	10.1 (95%CI: 6.3-13.7)	18.7 (95%CI: 14.5-NE)
Drilon[10]	Larotrectinib	122	Salivary, infantile fibrosarcoma, thyroid cancer, lung cancer, etc.	81	Not reached	Not reached	Not reached
	Entrectinib	54	Sarcoma, lung cancer, mammary analogue secretory carcinoma, etc.	58	10.4	11.2	20.9
Suh et al[11]	Larotrectinib	23	Soft tissue sarcoma	52.2		Not reached	Not reached
	Entrectinib	16	Soft tissue sarcoma	56.3		10.1	16.8
Demetri et al[12]	Larotrectinib	71	Sarcoma, salivary, NSCLC, etc.	87 (95%CI: 77-94)	Not reached	28.3 (95%CI: 16.8-NE)	44.4 (95%CI: 44.4-NE)
	Entrectinib	13	Sarcoma, NSCLC, salivary, breast, thyroid	46 (95%CI: 19-75)	10.3 (95%CI: 4.6-15.0)	11.0 (95%CI: 6.5-15.7)	16.8 (95%CI: 10.6-20.9)

TRKi: Tyrosine receptor kinase inhibitor; NSCLC: Non-small cell lung cancer; CI: Confidence interval; NE: Non-estimable.